Knights of Columbus Asset Advisors LLC decreased its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 44.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,579 shares of the company's stock after selling 2,845 shares during the quarter. Knights of Columbus Asset Advisors LLC's holdings in DaVita were worth $535,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. MML Investors Services LLC boosted its stake in shares of DaVita by 1.3% during the 3rd quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock worth $869,000 after acquiring an additional 68 shares during the period. Exchange Traded Concepts LLC boosted its position in DaVita by 8.3% during the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock worth $133,000 after purchasing an additional 68 shares during the period. Impact Partnership Wealth LLC increased its holdings in shares of DaVita by 3.7% in the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock valued at $290,000 after purchasing an additional 70 shares during the last quarter. Contravisory Investment Management Inc. raised its position in shares of DaVita by 1.2% in the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company's stock valued at $910,000 after purchasing an additional 73 shares during the period. Finally, Nilsine Partners LLC lifted its stake in shares of DaVita by 0.8% during the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company's stock worth $1,669,000 after buying an additional 92 shares during the last quarter. Institutional investors own 90.12% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently commented on the stock. StockNews.com lowered shares of DaVita from a "buy" rating to a "hold" rating in a research note on Friday, March 21st. Barclays upped their target price on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Cowen reissued a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat, DaVita presently has a consensus rating of "Hold" and a consensus target price of $166.33.
Get Our Latest Research Report on DaVita
DaVita Price Performance
DaVita stock traded up $1.36 during midday trading on Thursday, reaching $152.73. The company's stock had a trading volume of 410,680 shares, compared to its average volume of 783,449. The stock has a market cap of $12.22 billion, a PE ratio of 14.22, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 52 week low of $125.64 and a 52 week high of $179.60. The business has a 50-day moving average price of $157.96 and a 200-day moving average price of $157.53.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current year.
DaVita Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
